|GD - Online||Press Releases 2003|
7th Annual Meeting of
the GD, 1 - 2 April 2003
Dermopharmacy-Innovation Prize Awarded for the First Time
Interlocutors at the press conference were:Dr. Walter Wigger-Alberti (acting head of the department Dermocosmetics of the GD; director "Clinical Examination" at proDerm-Dermatological Research GmbH)
Prof. Dr. Dr. Thomas Ruzicka (scientific conference head; director at the Dermatological Clinic of Heinrich-Heine University, Düsseldorf)
Prof. Dr. Wolfgang Wiegrebe (president of the committee responsible for the Dermopharmacy-Innovation Prize; retired ordinary professor for pharmaceutical chemistry - Regensburg university)
Prof. Dr. Thomas L. Diepgen (director of the Institute and Outpatients' Clinic for Occupational and Social Medicine - University Clinical Center Heidelberg)
Prof. Dr. med. Hans Christian Korting (vice president of the GD, director of the Deutsche Mykologische Gesellschaft (German Mycological Society), Clinic and Outpatients' Clinic for Dermatology and Allergology, Clinical Center of the Ludwig-Maximilian-University, (LMU) Munich)
Dr. Joachim Kresken (GD president, pharmacist, Irmgardis-Pharmacy, Viersen)
Frank von Spee (imprint Publikation and PR, Hamburg)
(Bonn, 2.4.2003) In future the GD - Gesellschaft
für Dermopharmazie e.V. will pay tribute to outstanding innovations in the
field of Dermopharmacy with the newly conceived Dermopharmacy Innovation Prize
(DIP) in irregular intervals. The prize itself is a work of art made of glass
and designed for this particular purpose, representing a cross-section of skin.
On 1 April 2003 this prize was awarded for the first time in the frame of 7th
GD Annual Meeting in Bonn. Prize winner is Professor Dr. med. Jean Krutmann of
the Institut für Umweltmedizinische Forschung (Institute for Environmental
Medical Research) at Heinrich-Heine University Düsseldorf, for his outstanding
scientific work in the field of photobiology of skin.
Sunlight Impairs the DNA
If human skin is exposed to the sun, under the influence of the short-wave UV-B rays changes of the DNA are produced and thus disorders of the immune system conveying the growth of tumor cells. "It could be shown by means of animal experiments that a healthy immune system is able to reject tumor cells", professor Wiegrebe reports. To this end, foreign tumor cells have been transplanted to mice entailing a reaction of their immune system to these cells. However, if the mice had been irradiated with UV-B before, they were no longer able to fight against the transplanted tumor cells and as a consequence the tumor spread.
Repair Enzyme Entails a Swift DNA-regeneration in Skin
In a natural way human DNA regenerates only slowly as the injured parts have to be cut out, re-synthesized and refit into the DNA. In contrast to human beings, the Alga Anacystis nidulans produces a repair enzyme, the so-called photolyasis by which it protects itself from the UV-radiation of the sun. Under long-wave UV-light this enzyme splits cross-linked DNA-cords in corresponding separate cords, which can then be read off once again. Since the availability of photolyasis-containing sun protection and after-sun preparations, the repair effect of the enzyme can also be made use of for human skin. Krutmann observed that the human cells affected by the UV radiation regenerate much more rapidly under the influence of photolyasis. Already after a 30-minute exposure approximately 45 percent of the damages are reversed and the dermal immune system is even completely restored.
Overall Performance Honoured
Krutmann has also made an essential contribution to the clarification of UV-A
rays. They are equally dangerous because they entail the formation of aggressive
oxygen radicals which enhance early skin ageing and the development of the cutaneous
carcinoma as well as other light dermatoses. Moreover, Krutmann was concerned
with the clarification of genetically determined skin diseases, which are conditioned
by sunlight. Accordingly the GD awards the overall performance of professor Krutmann
as researcher in the field of dermal photobiology with its Dermopharmacy-Innovation
GD Society for Dermopharmacy interdisciplinary forum for questions concerning prevention and treatment of skin diseases
(Bonn, 2.4.2003) Which properties should skin care products available in the market have for persons with dry skin and skin prone to acne, bearing the attribute "dermocosmetic", respectively which tests should these products undergo? Which sun protection agents are suited for patients suffering from neurodermitis, acne or enhanced sensitivity to light? Is there a new approach concerning prevention and treatment of cutaneous carcinoma? For more than seven years pharmacists, physicians and other skin experts, who created a mutual scientific forum in cooperation with the GD Gesellschaft für Dermopharmazie e.V., deal with these and related questions.
The interdisciplinary field of Dermopharmacy is placed in the midst of medicine
and pharmacy. "Our field of activity deals with topics regarding the external
and internal application of drugs, medicinal products, cosmetics and food supplements
which serve the prevention and treatment of skin diseases", Dr. Joachim Kresken,
president of the GD explained. The spectrum stretches from new methods for the
treatment of widespread skin diseases as psoriasis, neurodermitis or fungal diseases
via dermocosmetic sun protection to recommendations towards professional skin
protection. Concerned with the respective subjects are departments with highly
qualified experts and other working groups.
The GD has committed itself to present latest research insights
and treatment methods not only to expert circles but also to the wide public.
Accordingly, the GD publishes special advisory brochures for consumers besides
guidelines and statements for expert circles. Relating to the subjects onychomycosis
and dry skin such advisory brochures are available in the meantime. Research results
both concerning new and also proven skin drugs as well as cosmetics have been
published in its dermopharmaceutic scientific magazine "DermoTopics"
which is available as printed magazine and online-version. Moreover, the GD organizes
a large number of further professional and information events. All guidelines
and position papers of the society as well as other information and advice regarding
the topics prevention and treatment of skin diseases are also retrievable at the
GD-homepage under www.gd-online.de.
Society for Dermopharmacy introduces guidelines for dermocosmetic sun protection and occupational skin protection products
(Bonn, 2.4.2003) Which sun
cream is qualified for oilyskin? Which properties should sun protecting products
for persons suffering from neurodermitis and other high-risk groups have and which
tests should they be subject to? In Germany so far there had only been as few
coherent standards as for agents, which are available for the protection of skin
from occupational strains. The GD Gesellschaft für Dermopharmazie e.V. has
recently presented the first guidelines for these two product categories established
by experts of different fields and thus contributed to a higher level of consumer
Proof of the Protective Effect by Experiments at Test Subjects
(Bonn, 2.4.2003) While it is generally known in the meantime that excessive sunbathing may lead to the black cutaneous carcinoma, the malignant melanoma, other skin cancer types, namely the prickle-cell carcinoma and basalioma are mostly neglected. However, these cancer types also denominated as "light skin cancer" are more frequent than the malignant melanoma. The GD Gesellschaft für Dermopharmazie e.V. has therefore founded a Task Force taking the dangers of the light cutaneous carcinoma into account.
The situation gives rise to concern. "In the frame of the increase of an average life expectancy - at present for women 80 years, respectively 74 for men in Germany - we face more and more intensely the phenomenon of aged skin", expounds the GD's vice-president professor Dr. med. Hans Christian Korting. "Particularly important for health and especially for skin ageing conditioned by exterior factors is the so-called extrinsic ageing. Predominantly due to a changed spare time comportment, a massive sun exposition over the decades also in Europe comes about. This leads in the end to an increased number of the black but also of the so-called light cutaneous carcinoma". For that reason the GD, integrating dermatologists, pharmacists, scientists as well as skin experts from the pharmaceutical and cosmetic industry has founded a study group for cutaneous carcinoma prevention - the Task Force "Licht.Hautkrebs.Prävention" (Light.Skin Cancer.Prevention) which has now been introduced to the public at the 7th Annual Meeting of the GD in Bonn. A focus is set above all on the clarification and research of the light skin cancer.
Rough light Tyloma as Preliminary Stage to Light Cutaneous Carcinoma
The spinocellular carcinoma (prickle-cell carcinoma of skin) is despite its frequent appearance relatively unknown due to the fact that metastases develop only seldom. However untreated, this carcinoma may, as the malignant melanoma, lead to death. In general the prickle-cell carcinoma only appears with persons over the age of 60. Affected are for the most part people with fair complexion who have exposed themselves intensely to the sun during their entire lifespan. A frequent preliminary stage is the so-called actinic keratosis, the rough light tyloma, by which already 40 percent of the over forty-year old are affected in Australia - but in Central Europe still a percentage of 10 to 15. A reddened skin area is formed with a brownish, thickened horny layer. In case the changed skin cells burst the limit from the epidermis to the dermis, the prickle-cell carcinoma comes into being, which proliferates cauliflower-like. "The risk that the light tyloma present with many persons becomes cancerous is estimated at up to 16 percent per year", according to professor Korting. The most frequently affected places are those which are most exposed to the sun - face, ears, the back of hands and lower arms as well as the bald head with men. At an early diagnosis and timely therapy start, the carcinoma respectively its preliminary stage, the actinic keratosis can be successfully treated. Besides traditional physical treatment methods as the cryo-therapy recently there are new forms of scientifically well-founded medicinal treatments comprising in particular an application of a gel with the active substance Diclofenac and the additive hyaluronic acid. Moreover, the so-called photodynamic therapy is applied lately based on a sensitizing substance (amino laevuline acid) in combination with light.
Basalioma - Most Widespread Type of Cutaneous Carcinoma in Central Europe
In Central Europe even more frequent than the spinocellular carcinoma is however the basalioma (basal-cell carcinoma). This skin cancer type does not develop metastases, but becomes continuously enlarged and destroys skin, tissue located underneath it and possibly even bones in this process. The most frequently affected skin areas as well as high-risk groups correspond to the ones of the prickle-cell carcinoma, whereas an increasing number of younger persons are affected with this disease. Basaliomae often appear as small even knots, which have a glossy surface. Later on they may turn reddish or brownish and get crusty or scaly. Equally a basalioma can be removed by different methods. After the removal a regular dermatological control is required due to the fact that if once a basalioma has appeared, it is probable that such tumours also develop at other locations, which however are no metastases. In case a basalioma is not completely removed, the remnants of the tumour may start to regrow.
Task Force Aims at Arousing the Public Interest
"It is our concern
to direct the public awareness to the light cutaneous carcinoma types", professor
Korting explained the objective of the GD Task Force "Licht.Hautkrebs.Prävention"
(Light.Skin-Cancer.Prevention), "also in the field of research we will considerably
intensify our efforts." Thus, the Task Force will push forward evidence-based
research concerning light cutaneous carcinoma types, establish diagnosis guidelines
for dermatologists and initiate the incorporation of these carcinoma types into
the carcinoma register. So far they are only classified as "Miscellaneous
Skin Cancer" in the WHO-classification ICD 173. "The major target however
is", professor Korting summarizes, "to call people's attention to the
fact that a skin-endangering behaviour is not only able to lead to the black cutaneous
carcinoma but to an even higher extent to the light skin cancer and that effective
sun protection by light protection products and appropriate clothing as well as
regular dermatological control represent the best way of prevention".
7th Annual Meeting of the GD - Society for Dermopharmacy introduced new therapy methods for eczema, neurodermitis and cutaneous carcinoma
Human resistance is determined by manifold factors: environmental influences as
UV-radiation, pollen or house dust mites, entail more and more frequently a deregulation
of the immune system. Often eczema or inflammatory skin diseases as neurodermitis
develop as a consequence. However, at the present time there is a series of new
therapies on hand which are able to control and regulate the reactions of the
immune system. In the course of 7th Annual Meeting of the GD - Gesellschaft für
Dermopharmazie e.V. on 1st and 2nd April 2003 in Bonn, in which approximately
200 dermatological experts from the fields dermatology, pharmacy and cosmetology
took part, these new treatment methods as well as other research results were
An additional focus of the GD's Annual Meeting was set on chronically inflammatory skin diseases as neurodermitis (atopical eczema) and psoriasis. At present roughly 15 percent of all children as well as one percent of adults are diseased with neurodermitis. There is an increasing tendency: every ten years these figures double. It can be assumed that the cause of neurodermitis lies among other causes in a genetically-conditioned overreaction of the immune system. Normally harmless factors as house dust mites or pollen alarm the immune system and induce that skin is overwhelmed with inflammatory cells which then cause the typical symptoms as itching and reddening. To date neurodermitis has predominantly been treated with cortisone-containing ointments, moisturizing creams and itching-soothing antihistamines. However, cortisone may have a skin-thinning effect making skin thus susceptible to a recurrence of the disease. With the novel substance class of the topical immune modulators (TIMs) there is for the first time an effective alternative to the treatment with cortisone. Topical immune modulators have a regulating effect on the equilibrium of the immune system. In the course of the allergic immune defence T-lymphocytes are activated in order to develop antibodies (immune globulin-E-antibodies, IgE) against the alleged dangerous factors, e.g. house dust mites. This process develops the known symptoms for the persons concerned. The topical immune modulators are able to penetrate the T-lymphocytes and to decelerate their activity. Thus the overreaction of the immune system is intercepted and the inflammation is able to heal.
In the case of psoriasis, which affects
about two million people in Germany other immunologically active substances, the
so-called "Biologicals" may help. These drugs also influence the immune
system and consequently intervene in the inflammation. "Biologicals"
are also helpful with rheumatism and inflammatory intestinal diseases. They are
in most cases administered in form of injections or infusions. The use of "Biologicals"
with inflammatory skin diseases is at present subject to worldwide intensive research.
Press Conference Bonn 2003
From left: Prof. Dr. med. Hans Christian Korting,
Frank von Spee (moderator), Dr Joachim Kresken
|Copyright © 2000 - 2014 Institute for Dermopharmacy GmbH email@example.com|